Charles Schwab
VINC

Charles Schwab’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Charles Schwab’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,985
Closed -$159K – 3669
2022
Q1 		$159K Hold
1,985
– – ﹤0.01% 3341
2021
Q4 		$405K Buy
1,985
+425
+27% +$106K ﹤0.01% 3216
2021
Q3 		$505K Buy
1,560
+700
+81% +$204K ﹤0.01% 3148
2021
Q2 		$224K Buy
+860
New +$262K ﹤0.01% 3264

Other funds holding VINC

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Charles Schwab's VINC Position: Q2 2022 in Review

Charles Schwab sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2022, closing a stake of 1,985 shares — an estimated $159K sold.

Charles Schwab first reported a position in VINC in Q2 2021 and held it in 4 quarters. The position peaked at $505K in Q3 2021. 51 funds tracked by Wall St. Rank hold VINC as of Q2 2022.

  • Charles Schwab reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Charles Schwab sold 1,985 Vincerx Pharma, Inc. Common Stock shares in Q2 2022, an estimated $159K.
  • Charles Schwab first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Charles Schwab's Vincerx Pharma, Inc. Common Stock position peaked at $505K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.